Catalyst Pharmaceuticals Inc (CPRX)

Oct 13, 2025

Catalyst Pharmaceuticals Shares Climb as New Drug Developments Spark Fresh Valuation Debate - Yahoo Finance

Oct 13, 2025

Oct 13, 2025

Can Catalyst Pharmaceuticals Inc. (CN2) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Opportunity Watchlist - newser.com

Oct 13, 2025

Oct 13, 2025

What institutional flow reveals about Catalyst Pharmaceuticals Inc.July 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com

Oct 13, 2025

Oct 13, 2025

Catalyst Pharmaceuticals (CPRX): Assessing Valuation on Clinical Progress and Expanding Rare Disease Pipeline - Sahm

Oct 13, 2025

Oct 12, 2025

Assessing Catalyst Pharmaceuticals’ Value After Recent Positive FDA Ruling in 2025 - Sahm

Oct 12, 2025

Oct 11, 2025

Catalyst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 11, 2025

Oct 10, 2025

Should Catalyst Pharmaceuticals’ (CPRX) Share Buyback and New Data Prompt a Fresh Look at Its Strategy? - Sahm

Oct 10, 2025

Oct 10, 2025

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com

Oct 10, 2025

Oct 10, 2025

Using Ichimoku Cloud for Catalyst Pharmaceuticals Inc. technicalsWatch List & Consistent Growth Equity Picks - newser.com

Oct 10, 2025

Oct 10, 2025

Published on: 2025-10-10 04:19:27 - newser.com

Oct 10, 2025

Oct 10, 2025

Will earnings trigger a reversal in Catalyst Pharmaceuticals Inc.Portfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com

Oct 10, 2025

Oct 09, 2025

Catalyst Pharmaceuticals (NASDAQ:CPRX) Earns "Hold (C+)" Rating from Weiss Ratings - MarketBeat

Oct 09, 2025

Oct 09, 2025

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences - GlobeNewswire

Oct 09, 2025

Oct 09, 2025

Catalyst Pharmaceuticals to Present Research on Duchenne Muscular Dystrophy and Lambert Eaton Myasthenic Syndrome at Upcoming Scientific Conferences - Quiver Quantitative

Oct 09, 2025

Oct 09, 2025

3 Presentations: Catalyst Pharmaceuticals to present DMD & LEMS data at Oct 2025 conferences - Stock Titan

Oct 09, 2025

Oct 09, 2025

Real time breakdown of Catalyst Pharmaceuticals Inc. stock performance2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com

Oct 09, 2025

Oct 09, 2025

Published on: 2025-10-09 06:27:04 - newser.com

Oct 09, 2025

Oct 09, 2025

Catalyst Pharmaceuticals Delivers Growth But Faces Narrow Pipeline Risk - Finimize

Oct 09, 2025

Oct 09, 2025

Published on: 2025-10-09 00:54:28 - newser.com

Oct 09, 2025

Oct 08, 2025

Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Jacobus Pharmaceutical, Catalyst Pharmaceuticals - Barchart.com

Oct 08, 2025

Oct 08, 2025

Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance

Oct 08, 2025

Oct 08, 2025

What do Analysts Think About Catalyst Pharmaceuticals (CPRX)? - MSN

Oct 08, 2025

Oct 07, 2025

14 Biotech Stocks with High Potential - Insider Monkey

Oct 07, 2025

Oct 06, 2025

Will Catalyst Pharmaceuticals Inc. rebound enough to break evenTrade Risk Assessment & Daily Technical Forecast Reports - newser.com

Oct 06, 2025

Oct 06, 2025

Published on: 2025-10-06 05:08:49 - newser.com

Oct 06, 2025

Oct 06, 2025

Detecting price anomalies in Catalyst Pharmaceuticals Inc. with AIEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com

Oct 06, 2025

Oct 05, 2025

A Closer Look at Catalyst Pharmaceuticals (CPRX) Valuation as Shares Remain Steady This Week - Sahm

Oct 05, 2025

Oct 05, 2025

Order flow analysis tools used on Catalyst Pharmaceuticals Inc.Weekly Trade Review & Capital Efficiency Focused Strategies - newser.com

Oct 05, 2025

Oct 04, 2025

Wealth Enhancement Advisory Services LLC Lowers Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - Defense World

Oct 04, 2025

Oct 04, 2025

Wall Street Zen Downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Hold - MarketBeat

Oct 04, 2025

Oct 03, 2025

Why Catalyst Pharmaceuticals Inc. (CN2) stock could break out in 2025July 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com

Oct 03, 2025

Oct 03, 2025

Catalyst Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com

Oct 03, 2025

Oct 03, 2025

What macro factors could drive Catalyst Pharmaceuticals Inc. (CN2) stock higherPortfolio Update Report & Weekly High Conviction Trade Ideas - newser.com

Oct 03, 2025

Oct 03, 2025

Published on: 2025-10-03 06:09:02 - newser.com

Oct 03, 2025

Oct 03, 2025

Using flow based indicators on Catalyst Pharmaceuticals Inc.2025 Big Picture & Daily Stock Trend Watchlist - newser.com

Oct 03, 2025

Oct 03, 2025

Historical volatility pattern of Catalyst Pharmaceuticals Inc. visualizedJuly 2025 Breakouts & Reliable Price Breakout Alerts - newser.com

Oct 03, 2025

Oct 03, 2025

Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - The Manila Times

Oct 03, 2025

Oct 02, 2025

Share Repurchase Program Initiated by Catalyst Pharmaceuticals (NASDAQ:CPRX) Board of Directors - Defense World

Oct 02, 2025

Oct 01, 2025

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program - GlobeNewswire

Oct 01, 2025

Oct 01, 2025

Catalyst Pharma Announces $200M Share Repurchase Program - TipRanks

Oct 01, 2025

Oct 01, 2025

Catalyst Pharmaceuticals, Inc. authorizes a Buyback Plan. - MarketScreener

Oct 01, 2025

Oct 01, 2025

Catalyst Pharmaceuticals, Inc. announces an Equity Buyback for $200 million worth of its shares. - MarketScreener

Oct 01, 2025

Oct 01, 2025

Catalyst Pharma Announce New Share Repurchase Program Of $200 Mln - Nasdaq

Oct 01, 2025

Oct 01, 2025

Catalyst Pharmaceuticals Approves $200 Million Share Repurchase Program - MarketScreener

Oct 01, 2025

Oct 01, 2025

Catalyst Pharmaceuticals authorizes $200 million share buyback program By Investing.com - Investing.com Canada

Oct 01, 2025